DDInter463 DDInter1628
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Dacarbazine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) skin cancer
skin cancer {u} (Disease) is associated with {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) melanoma
melanoma {u} (Disease) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) pancreatic cancer
pancreatic cancer {u} (Disease) downregulates {v} (Gene) SLC25A4
SLC25A4 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) melanoma
melanoma {u} (Disease) downregulates {v} (Gene) CAMK1D
CAMK1D {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
peripheral nervous system neoplasm {u} (Disease) is associated with {v} (Gene) AKT1
AKT1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) muscle cancer
muscle cancer {u} (Disease) resembles {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) pancreatic cancer
pancreatic cancer {u} (Disease) upregulates {v} (Gene) ELF4
ELF4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dacarbazine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) and {u} (Diease) associated with {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dacarbazine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Dacarbazine (Compound) treats skin cancer (Disease) and skin cancer (Disease) is associated with PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Dacarbazine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Dacarbazine (Compound) treats melanoma (Disease) and melanoma (Disease) downregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Dacarbazine (Compound) treats pancreatic cancer (Disease) and pancreatic cancer (Disease) downregulates SLC25A4 (Gene) and SLC25A4 (Gene) is downregulated by Ruxolitinib (Compound)
Dacarbazine (Compound) treats melanoma (Disease) and melanoma (Disease) downregulates CAMK1D (Gene) and CAMK1D (Gene) is bound by Ruxolitinib (Compound)
Dacarbazine (Compound) treats peripheral nervous system neoplasm (Disease) and peripheral nervous system neoplasm (Disease) is associated with AKT1 (Gene) and AKT1 (Gene) is downregulated by Ruxolitinib (Compound)
Dacarbazine (Compound) treats muscle cancer (Disease) and muscle cancer (Disease) resembles hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Dacarbazine (Compound) treats pancreatic cancer (Disease) and pancreatic cancer (Disease) upregulates ELF4 (Gene) and ELF4 (Gene) is upregulated by Ruxolitinib (Compound)
Dacarbazine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates RET (Gene) and hematologic cancer (Diease) associated with RET (Gene) and RET (Gene) is bound by Ruxolitinib (Compound)